Coherus Oncology

CHRS · NASDAQ

$1.00+$0.0413 (+4.31%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $0.9587

CHRS analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $7.14 (+614.0% upside)

Low: $4.04
Now: $1.00
High: $10.50

Upgrades and downgrades

The latest rating actions, newest first

CHRS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Guggenheim	Aug 7, 2026	Maintains	Buy	$12.00 → $10.00	33%
Guggenheim	May 11, 2026	Initiates	Buy	$12.00	—
Oppenheimer	Jan 22, 2026	Initiates	Outperform	$10.00	43%

The case for and against

Updated Oct 19, 2025

Bull case

Coherus Oncology Inc has demonstrated significant advancements with its pipeline, particularly through the partial responses seen in heavily pretreated PD-1 refractory patients, which suggest that CHS-114 may effectively convert "cold" tumors into "hot" tumors, enhancing the efficacy of PD-1 treatments. The establishment of proof of mechanism during CHS-114 monotherapy showcases critical immunological changes, including Treg cell depletion and an increase in CD8+ T cells, indicative of promising anti-tumor activity. This compelling clinical data underscores Coherus's potential to innovate cancer treatment strategies and drive synergies from its integrated portfolio, including LOQTORZI and CHS-114, enhancing the company’s future growth outlook.

Bear case

Coherus Oncology faces significant regulatory and clinical risks, as several of its products have yet to receive approval, which could hinder future revenue generation. Additionally, the company competes against larger firms in the oncology market, posing threats of pricing erosion that may adversely affect its profitability. Moreover, low response rates and brief durations of efficacy for its treatments raise concerns regarding the commercial viability of its pipeline, highlighting the urgency of addressing unmet medical needs.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.